These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33798685)

  • 1. Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity.
    Sui D; Tang X; Ding J; Wang Y; Qin Y; Zhang N; Liu X; Deng Y; Song Y
    Int J Pharm; 2021 Jun; 602():120552. PubMed ID: 33798685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives].
    Song YZ; Huang ZJ; Luo X; Wang MJ; Zheng JH; Shi J; Deng YH
    Yao Xue Xue Bao; 2016 Feb; 51(2):316-24. PubMed ID: 29856587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
    Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
    Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
    Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives.
    Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y
    Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
    She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
    Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of TAMs with freeze-dried monosialotetrahexosylganglioside and sialic acid-octadecylamine co-modified liposomes remodels the tumor microenvironment and enhances anti-tumor activity.
    Wei L; Zhao D; Sun W; Lin L; Sui D; Li W; Gui Y; Wang J; Deng Y; Song Y
    Eur J Pharm Biopharm; 2023 Mar; 184():50-61. PubMed ID: 36682511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
    Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of phospholipid composition on pharmacokinetics and biodistribution of epirubicin liposomes.
    Sha X; Guo J; Chen Y; Fang X
    J Liposome Res; 2012 Mar; 22(1):80-8. PubMed ID: 22022836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells.
    Wang YJ; Tang L; Lu XH; Liu JT; Wang YY; Geng HX; Li XT; An Q
    J Liposome Res; 2023 Jun; 33(2):197-213. PubMed ID: 36440599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
    Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
    Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
    Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
    Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy.
    Li C; Qiu Q; Liu M; Liu X; Hu L; Luo X; Lai C; Zhao D; Zhang H; Gao X; Deng Y; Song Y
    Biomater Sci; 2020 Apr; 8(8):2189-2201. PubMed ID: 32096498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selection of animal models influences the assessment of anti-tumor efficacy: promising sialic acid-conjugate modified liposomes demonstrate remarkable therapeutic effects in diverse mouse strains.
    Wei L; Lin L; Wang J; Guan X; Li W; Gui Y; Liao S; Wang M; Li J; Deng Y; Song Y
    Drug Deliv Transl Res; 2024 Jul; 14(7):1794-1809. PubMed ID: 38165530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.